Qvin has announced that its Q-Pad A1c tests are now eligible for FSA/HSA coverage, following the technology’s historic FDA clearance in January 2024. This development makes the first FDA-cleared menstrual blood testing device more financially accessible to Americans managing their health through these tax-advantaged accounts.
The Q-Pad offers a novel approach to health monitoring through menstrual blood testing, with particular value for diabetes management through A1c level measurements. The system uses a pad with a removable strip to collect menstrual blood, which is then analyzed in a CLIA-Certified laboratory, with results delivered through the Qvin app.
“With the first ever FDA-cleared menstrual blood health test, Qvin is paving the way to important new opportunities for women’s health and this is just the beginning,” said Dr. Sara Naseri, Qvin Co-founder, Medical Doctor, and scientist. “We are simplifying routine testing, and freeing up resources that can be used on providing care and ultimately our goal is to make health care much more accessible.”
Beyond diabetes monitoring, the company’s research with Stanford University School of Medicine has validated the technology’s potential for testing various biomarkers related to conditions including anemia, fertility issues, perimenopause, endometriosis, and thyroid health. The company is also exploring applications for HPV screening and reproductive hormone monitoring.
